What regenerative therapy Tempe means for a sore joint

Years of use can leave a joint sore and stiff

Cartilage is the smooth layer covering the ends of bones inside a joint, and it helps those bones slide past each other. That layer may thin over time, while old injuries can leave swelling or stiffness. A tendon is the strong cord joining muscle to bone near the joint. It can become sore after too much work. Weak muscles may also add strain during walking or lifting.

Soreness alone doesn't reveal which part is causing trouble.

Gentle movement often helps more than complete rest

Easy motion and brief walks can prevent the joint from tightening. Heat may ease morning stiffness, while cold can calm swelling after activity. Ask a doctor if common medicine works safely alongside the other drugs you take. Physical therapy can build strength without making the joint work too hard.

Stop when an activity makes the soreness keep rising.

QC Kinetix offers non-surgical choices for joint soreness

The clinic offers regenerative treatments, a broad name for non-surgical joint shots made with material from the body. PRP stands for platelet-rich plasma. To make it, a health worker takes blood and uses a spinning machine to separate liquid holding extra platelets. A medical provider then gives a shot that places the liquid in the sore joint. The concentrated form contains a larger share of platelets. Medical providers are the health workers who inspect the joint and give care. Ask the clinic whether a physician assistant, nurse practitioner, or doctor will see you. The clinic calls its blood-prepared care biologic therapies or natural pain treatments. Joint preservation means trying non-surgical care before knee or hip surgery.

These choices won't fit every sore joint.

A visit is worthwhile when soreness changes daily life

Get the joint checked when soreness continues after easy movement, heat, or cold. The health worker first reviews past health and then examines the sore area. Earlier X-ray or MRI reports may help. If surgery has come up, that worker can discuss other choices for a knee or hip.

A joint that is hot, very swollen, and paired with fever needs urgent care.

Sources

1. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

3. The strongest recent POSITIVE signal: a meta-analysis of 10 RCTs (818 patients, KL I-III) found intra-articular MSC injection beat hyaluronic acid at 12 months on WOMAC total (MD -10.22), VAS (MD -1.31) and on the MRI Whole-Organ Magnetic Resonance Imaging Score (MD -26.01), all reaching the minimal clinically important difference, with no significant difference in adverse events. Recorded here at full weight: this result and the negative RESTORE and Mautner trials are both in the literature, and an honest page reports both.

   Jin WS, et al. — Mesenchymal Stem Cells Injection Is More Effective Than Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis With Similar Safety: A Systematic Review and Meta-analysis.. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025. DOI: 10.1016/j.arthro.2024.07.027.

4. A systematic review of the discordance between clinical and radiographic knee osteoarthritis: many people with severe-looking x-rays have little pain, and many with disabling pain have modest radiographic change. This is the reason a post-treatment scan is a poor proxy for how someone feels, in either direction.

   Bedson J, et al. — The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature.. BMC musculoskeletal disorders, 2008. DOI: 10.1186/1471-2474-9-116.

5. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

6. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

   Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.

7. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.